Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | RGS12 | O14924 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11415974 | 0.85 | CYP3A4 (0.51) | MEN1POLBKMT2ARGS12USP2 | |
| Butane SCHEMBL11876142 | 0.80 | MEN1 (0.65) | MEN1POLBKMT2ARGS12USP2 | |
| SCHEMBL31006472 | 0.78 | IDO1 (0.52) | MEN1POLBKMT2ARGS12USP2 | |
| SCHEMBL9437190 | 0.77 | IDO1 (0.44) | MEN1POLBKMT2ARGS12MAPT | |
| SCHEMBL11694697 | 0.76 | MAPT (0.60) | MEN1POLBKMT2ARGS12USP2 | |
| SCHEMBL28495677 | 0.76 | MEN1 (0.60) | MEN1POLBKMT2ARGS12USP2 | |
| Phthalimide SCHEMBL1672293 | 0.73 | TDP1 (0.51) | MEN1POLBKMT2ARGS12USP2 | |
| SCHEMBL8519239 | 0.73 | POLB (0.46) | MEN1POLBKMT2ARGS12USP2 | |
| SCHEMBL30069272 | 0.73 | CNR1 (0.57) | MEN1POLBKMT2ARGS12USP2 | |
| SCHEMBL19630392 | 0.73 | PARP1 (0.47) | MEN1POLBKMT2ARGS12USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215815-A1 | Neurotrophin antagonist compositions | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-27 | — | — | US | claimed |
| EP-0930883-B1 | NEUROTROPHIN ANTAGONISTS FOR THE TREATMENT OF EPILEPSY, ALZHEIMER'S DISEASE AND PAIN | ALLELIX BIOPHARMA (CA) | 2006-01-11 | — | — | EP | claimed |
| US-20050250807-A1 | Neurotrophin antagonist compositions | TEHIM ASHOK | 2005-11-10 | — | — | US | claimed |
| US-20020169182-A1 | Neurotrophin antagonist compositions | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2002-11-14 | — | — | US | claimed |
| EP-0930883-A1 | NEUROTROPHIN ANTAGONIST COMPOSITIONS | Allelix Biopharmaceuticals Inc. (CA) | 1999-07-28 | — | — | EP | claimed |
| WO-1998017278-A1 | NEUROTROPHIN ANTAGONIST COMPOSITIONS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1998-04-30 | — | — | WO | claimed |
| US-20090215815-A1 | Neurotrophin antagonist compositions | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-27 | — | — | US | disclosed |
| US-20080287484-A1 | Neurotrophin antagonist compositions | TEHIM ASHOK | 2008-11-20 | — | — | US | disclosed |
| US-7291629-B2 | Neurotrophin antagonist compositions | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-11-06 | — | — | US | disclosed |
| EP-0930883-B1 | NEUROTROPHIN ANTAGONISTS FOR THE TREATMENT OF EPILEPSY, ALZHEIMER'S DISEASE AND PAIN | ALLELIX BIOPHARMA (CA) | 2006-01-11 | — | — | EP | disclosed |
| US-20050250807-A1 | Neurotrophin antagonist compositions | TEHIM ASHOK | 2005-11-10 | — | — | US | disclosed |
| US-20020169182-A1 | Neurotrophin antagonist compositions | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2002-11-14 | — | — | US | disclosed |
| EP-0930883-A1 | NEUROTROPHIN ANTAGONIST COMPOSITIONS | Allelix Biopharmaceuticals Inc. (CA) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998017278-A1 | NEUROTROPHIN ANTAGONIST COMPOSITIONS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215815-A1 | Neurotrophin antagonist compositions | NGF, NTRK2, BDNF | MEN1 4269/4885POLB 2700/4885KMT2A 3457/4885 |
| US-20050250807-A1 | Neurotrophin antagonist compositions | NGF, NTRK2, BDNF | MEN1 4175/4885POLB 2609/4885KMT2A 3637/4885 |
| US-20020169182-A1 | Neurotrophin antagonist compositions | NTRK2, NGF, BDNF | MEN1 4752/4885POLB 3133/4885KMT2A 3113/4885 |
| US-20080287484-A1 | Neurotrophin antagonist compositions | NGF, NTRK2, BDNF | MEN1 4146/4885POLB 2702/4885KMT2A 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.